– UK, London – Shield Therapeutics plc (LON: STX), a commercial-stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru/Accrufer, today announced the appointment of Dr Christian Schweiger to its Board as a Non-Executive Director effective immediately.
“I am delighted that Christian has agreed to join the board of Shield bringing his previous knowledge of the Company and Feraccru, and also his extensive experience in medical affairs and clinical development.” said Board Chairman, Hans Peter Hasler.
About Dr Christian Schweiger
Dr. Schweiger was a co-founder of Shield in 2008 and was more recently employed by the Company between March 2016 and April 2017 in a senior medical science capacity. Dr Schweiger is an entrepreneurial senior medical affair and clinical development executive with substantial experience working with both large and small pharmaceutical companies.
Dr Schweiger is also Lecturing Professor in Pharmaceutical Medicine at the University of Essen and actively working with the different international patient and professional associations.
Dr. Schweiger currently owns shares representing 3.5% of the issued share capital and therefore is not considered to be independent.
About Shield Therapeutics plc
Shield is a de-risked, commercial-stage, speciality pharmaceutical company delivering innovative pharmaceuticals to address patients’ unmet medical needs. The Company’s clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group’s lead product, Feraccru/ Accrufer has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer with Shield currently in the process of selecting a commercialisation partner. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the development and commercialisation of Feraccru/Accrufer in China, Hong Kong, Macau and Taiwan.
For more information: https://www.shieldtherapeutics.com
About Feraccru/Accrufer
Feraccru/Accrufer is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia that has been shown to be an efficacious and well-tolerated therapy in a range of controlled phase 3 trials, and offers a compelling alternative to IV iron for those patients unable to tolerate salt-based oral iron therapies and wish to avoid the complexities of infusion-based iron therapies.
When salt-based oral iron therapies are ingested they can cause a range of mild-to-severe gastrointestinal tract adverse events, including nausea, bloating and constipation through the release and subsequent reactivity of free iron in the GI tract, leading to poor tolerability, reduced patient compliance and ultimately treatment failure. Feraccru/Accrufer is not an iron salt and, as a result, it does not routinely cause the same treatment-limiting intolerance issues of salt-based iron therapies, whilst the iron from the ferric maltol molecule can be readily absorbed.
Prior to Feraccru/Accrufer, IV iron therapies were the only realistic alternative treatment option for iron deficient patients with or without anaemia intolerant of or unwilling to be treated salt-based oral iron therapies. However, use of such an invasive, costly, inconvenient and complex to administer treatment option, which is associated with potentially life-threatening and spontaneous hypersensitivity reactions, means there remains a clear unmet medical need for these patients to have access to an effective therapy that is well-tolerated, convenient and does not require hospital-based administration. Feraccru/Accrufer meets those requirements.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
